EcoDrugPlus

5'-Nucleotidase Ecto

Ensembl ID : ENSAMXG00000042752
Gene Symbol: NT5E
3 Cross references
206 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1a B

Ensembl ID : ENSAMXG00000024875
Gene Symbol: HTR1AB
1 Cross references
138 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 1b

Ensembl ID : ENSAMXG00000025153
Gene Symbol: HTR1B
1 Cross references
65 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSAMXG00000001352
Gene Symbol: HTR2B
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSAMXG00000024961
Gene Symbol: HTR1B
4 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSAMXG00000017400
Gene Symbol: HTR1F
4 Cross references
112 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSAMXG00000025034
Gene Symbol: HTR1F
4 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSAMXG00000004978
Gene Symbol: HTR2A
1 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSAMXG00000030762
Gene Symbol: HTR2C
1 Cross references
154 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSAMXG00000032285
Gene Symbol: LOC103044140
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSAMXG00000005840
Gene Symbol: HTR3A
3 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSAMXG00000044061
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).